Active Biotech AB Interim report January - March 2010

* Reuters is not responsible for the content in this press release.

Thu Apr 22, 2010 2:44am EDT 

  LUND, SWEDEN, Apr 22 (MARKET WIRE) -- 

Laquinimod - Teva extends its marketing and distribution rights for
laquinimod

    TASQ - preparations for Phase III trials under way

    ANYARA - exploratory combination data presented

    57-57 - exploratory clinical trial in progress

    ISI - project proceeding according to plan

    RhuDex(TM) - preclinical studies in progress

    Net sales of SEK 2.8 M (2.2)

    Operating loss of SEK 51.0 M (loss: 63.7)

    Loss after tax of SEK 53.5 M (loss: 62.2)

    Loss per share for the period amounted to SEK 0.83 (loss: 1.21)

    After the end of the period a directed share issue raised approximately
SEK 149 M for the company


For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95

Goeran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0)46-19 11 54

Hans
Kolam
CFO
Tel: +46 (0)46-19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

    
This report is also available at www.activebiotech.com



[HUG#1406538]

     Active Biotech Interim report January-March 2010:
http://hugin.info/1002/R/1406538/359991.pdf

    



Copyright 2010, Market Wire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.